Please login to the form below

Not currently logged in
Email:
Password:

Aduro

This page shows the latest Aduro news and features for those working in and with pharma, biotech and healthcare.

J&J moves quickly ahead with trials of myeloma CAR-T

J&J moves quickly ahead with trials of myeloma CAR-T

Earlier this month it bought oncolytic virus player Benevir Biopharm for $140m upfront and up to $900m in milestones, and also has a collaboration with Aduro for cancer vaccine ADU-214

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.

  • Pharma deals in March 2015 Pharma deals in March 2015

    One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic

  • Pharma deals during October 2014 Pharma deals during October 2014

    on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform. ... Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics